Quarterly Result23 Apr 2025, 10:02 pm
Thyrocare Technologies Ltd Reports Q4FY25 Revenue of INR 187.2 Cr with 21% YoY Growth
AI Summary
Thyrocare Technologies Limited, a leading healthcare diagnostics company, announces their results for the quarter ended March 31, 2025. The consolidated revenue increased by 21% YoY, with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively. Total volume in FY25 grew to 167.9 million. Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%. Standalone normalized EBITDA grew by 72% YoY, while PAT increased by 72% YoY. Consolidated normalized EBITDA grew by 78% YoY, while PAT increased by 88% YoY. The company has recommended a final dividend of INR 21 per equity share and has cash reserves of INR 191.8 Cr as of March 2025. New labs have been opened in Bhagalpur and Kashmir.
Key Highlights
- Revenue of INR 187.2 Cr in Q4FY25 with a growth of 21% YoY
- Consolidated revenue increased by 21% YoY
- Pathology and Radiology segments grew by 23% YoY and 7% YoY respectively
- Standalone normalized EBITDA grew by 72% YoY, while PAT increased by 72% YoY
- Consolidated normalized EBITDA grew by 78% YoY, while PAT increased by 88% YoY